Houston, United States
Radiomer Therapeutics is a novel player in the radiopharmaceutical industry, having been founded in 2023. The company is pioneering a radioligand therapy platform that utilizes Raptamersᵀᴹ, which are peptide-oligonucleotide hybrids employed as a targeting vector. With its innovative approach, Radiomer Therapeutics positions itself at the forefront of advanced medical therapies.
Despite its cutting-edge developments, there appears to be a mismatch in the contextual content provided, which includes references to an e-commerce sector in its tagline. However, focusing on the company's core domain, the latest pre-seed investment of €35.00K was secured in March 2020 from investor Alexander Meinhart.
Based in the United States, Radiomer Therapeutics presents a compelling opportunity for investors keen on supporting promising technologies in the healthcare sector. Its innovative platform holds potential for significant advancements in radiopharmaceuticals, making it an attractive prospect for venture capital infusion.
